New cocktail of drugs aims to tackle tough colorectal cancer
NCT ID NCT07106034
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This phase 2 trial is testing whether adding two immune-boosting drugs (ongericimab and toripalimab) to standard second-line chemotherapy can shrink tumors in people with advanced MSS/pMMR colorectal cancer. The study enrolls 32 adults whose cancer progressed after first-line treatment. Participants receive one of two chemotherapy regimens depending on their prior treatment, plus the two study drugs and bevacizumab. The main goal is to see how many patients respond, with secondary goals including how long the response lasts and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ongericimab, toripalimab, bevacizumab, and chemotherapy (FOLFOX or FOLFIRI)
- What this could lead to
- If successful, this could offer a new second-line treatment option for people with a hard-to-treat form of colorectal cancer that has stopped responding to initial therapy.
- What could go wrong
- This is a small, early-phase trial with only 32 participants and no comparison group, so results may not apply broadly. The combination of multiple drugs also raises the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pudong Hospital
RECRUITINGShanghai, Shanghai Municipality, 201399, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat colorectal tumors?
- New drug combo aims to outperform standard therapy for advanced colorectal cancer
- Cottonseed compound plus immunotherapy takes on tough colorectal cancer
- New drug cocktail hopes to tackle advanced colon cancer
- New targeted combo aims to outsmart Hard-to-Treat colorectal cancer
- New injection could spare cancer patients from repeated belly drains